CD95L pro-drug: a novel Swiss Army Knife in cancer therapy?
Kassahn
D
D
Division of Immunopathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Nachbur
U
U
Brunner
T
T
D000951:Antigens, Neoplasm / Q000378:metabolism; D017209:Apoptosis; D015195:Drug Design; D053222:Fas Ligand Protein / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular; D009369:Neoplasms / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D010447:Peptide Hydrolases / Q000378:metabolism; D013601:T-Lymphocytes / Q000502:physiology; D019014:fas Receptor / Q000378:metabolism
D000951:Antigens, Neoplasm; D053222:Fas Ligand Protein; D019014:fas Receptor; D010447:Peptide Hydrolases